Related Experiment Video
Updated: Aug 17, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
New antimetabolites in the treatment of human malignancies
1Medicine Section, National Cancer Institute, Bethesda, MD 20892.
Abstract:
Several new antimetabolites have been evaluated in clinical trials in recent years. Those with the most promising activity include the structurally related purine analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin. These compounds have shown impressive activity against a broad spectrum of indolent lymphoproliferative disorders, including hairy-cell leukemia, chronic lymphocytic leukemia, and low-grade non-Hodgkin's lymphomas. They may also be useful in the treatment of acute leukemias. In contrast, they lack activity against common solid tumors. They have been generally well tolerated in large clinical trials; however, each of them is myelosuppressive and immunosuppressive. It is unlikely that any one of these drugs, when used as a single agent, will provide optimal therapy for any disease other than, possibly, hairy-cell leukemia. Combinations with other cytotoxic agents and biologics are in development, and perhaps they will lead to more effective regimens in the future.
Insights
New purine analog antimetabolites show promise for indolent leukemias and lymphomas. While generally well-tolerated, combinations are needed for optimal treatment beyond hairy-cell leukemia.
Area of Science:
- Oncology
- Pharmacology
Background:
- Recent clinical trials have evaluated novel antimetabolites.
- Purine analogs like fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin demonstrate significant therapeutic potential.
Purpose of the Study:
- To review the efficacy and tolerability of new antimetabolites.
- To assess their role in treating lymphoproliferative disorders and acute leukemias.
Main Methods:
- Clinical trial data evaluation.
- Review of antimetabolite activity against various hematologic malignancies and solid tumors.
Main Results:
- Purine analogs exhibit strong activity against indolent lymphoproliferative disorders (hairy-cell leukemia, chronic lymphocytic leukemia, low-grade non-Hodgkin's lymphomas) and potentially acute leukemias.
- These agents lack efficacy against common solid tumors.
- Myelosuppression and immunosuppression are key side effects; single-agent therapy is likely suboptimal except possibly for hairy-cell leukemia.
Conclusions:
- New purine analog antimetabolites are effective in specific hematologic cancers.
- Combination therapies are under development to enhance treatment outcomes and overcome limitations of single-agent use.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules
Tumor Immunotherapy
Antiviral Nucleoside Inhibitors